NOVAVAX INC
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. FORM 10-K SUMMARY
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| NOVAVAX, INC. | |
| By: | /s/ John C. Jacobs |
| John C. Jacobs | |
| President and Chief Executive Officer |
Date: February 28, 2024
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:
| Name | Title | Date |
|---|---|---|
| /s/ John C. Jacobs | President and Chief Executive Officer and Director (Principal Executive Officer) | February 28, 2024 |
| John C. Jacobs | ||
| /s/ James P. Kelly | Executive Vice President, Chief Financial Officer, and Treasurer (Principal Financial and Accounting Officer) | February 28, 2024 |
| James P. Kelly | ||
| /s/ James F. Young | Chairman of the Board of Directors | February 28, 2024 |
| James F. Young | ||
| /s/ Gregg H. Alton | Director | February 28, 2024 |
| Gregg H. Alton | ||
| /s/ Richard H. Douglas | Director | February 28, 2024 |
| Richard H. Douglas | ||
| /s/ Rachel K. King | Director | February 28, 2024 |
| Rachel K. King | ||
| /s/ Margaret G. McGlynn | Director | February 28, 2024 |
| Margaret G. McGlynn | ||
| /s/ David M. Mott | Director | February 28, 2024 |
| David M. Mott | ||
| /s/ Richard J. Rodgers | Director | February 28, 2024 |
| Richard J. Rodgers | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Years ended December 31, 2023, 2022, and 2021
Contents
| Reports of Independent Registered Public Accounting Firm (PCAOB ID:42) | F- 2 |
|---|---|
| Consolidated Statements of Operations and Statements of Comprehensive Loss for the years ended December 31, 2023, 2022, and 2021 | F- 6 |
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F- 7 |
| Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the years ended December 31, 2023, 2022, and 2021 | F- 8 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023, 2022, and 2021 | F- 9 |
| Notes to Consolidated Financial Statements | F- 10 |
F- 1
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.